Ticker > Company >

Pfizer share price

Pfizer Ltd.

NSE: PFIZER BSE: 500680 SECTOR: Pharmaceuticals & Drugs  1.52 L   444   55

5395.00
-36.00 (-0.66%)
NSE: Today, 01:54 PM

Price Summary

Today's High

₹ 5431

Today's Low

₹ 5389

52 Week High

₹ 6451.15

52 Week Low

₹ 3701

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

24680.9 Cr.

Enterprise Value

21882.42 Cr.

No. of Shares

4.57 Cr.

P/E

32.15

P/B

5.85

Face Value

₹ 10

Div. Yield

3.05 %

Book Value (TTM)

₹  921.88

CASH

2800.98 Cr.

DEBT

2.5 Cr.

Promoter Holding

63.92 %

EPS (TTM)

₹  167.79

Sales Growth

4.02%

ROE

19.65 %

ROCE

26.21%

Profit Growth

39.23 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Pfizer Ltd.

Becosules Folvite VIAGRA COREX LS RABEPRAZOLE GELUSIL BRONCOVIT WYSOLONE ANACIN Zavicefta Zinforo Meronem Magnex Zosyn

Index Presence

The company is present in 20Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year4.02%
3 Year-4.4%
5 Year1.18%

Profit Growth

1 Year39.23%
3 Year7.81%
5 Year8.56%

ROE%

1 Year19.65%
3 Year18.8%
5 Year19.38%

ROCE %

1 Year26.21%
3 Year25.38%
5 Year25.91%

Debt/Equity

0.0006

Price to Cash Flow

37.41

Interest Cover Ratio

120.54

CFO/PAT (5 Yr. Avg.)

0.77519054840601

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 63.92 0.00
Dec 2024 63.92 0.00
Sep 2024 63.92 0.00
Jun 2024 63.92 0.00
Mar 2024 63.92 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 25.3821333333333% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 120.54.
  • The Company has been maintaining an effective average operating margins of 30.5291314044038% in the last 5 years.
  • Company’s PEG ratio is 0.81967589422566.
  • The company has an efficient Cash Conversion Cycle of 21.8583 days.
  • Company has a healthy liquidity position with current ratio of 6.1682.
  • The company has a high promoter holding of 63.92%.

 Limitations

  • The company has shown a poor profit growth of 7.81076076897571% for the Past 3 years.
  • The company has shown a poor revenue growth of -4.3990006351423% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 546.63 562.86 588.59 537.99 591.91
Total Expenditure 357.2 385.37 399.34 392 364.41
Operating Profit 189.43 177.49 189.25 145.99 227.5
Other Income 75.13 41.84 43.07 42.76 44.58
Interest 6.95 2.11 2.1 1.51 2.69
Depreciation 13.75 14.6 14.99 14.8 16.4
Exceptional Items 0 0 0 0 172.81
Profit Before Tax 243.86 202.62 215.23 172.44 425.8
Tax 65 51.91 56.88 44.84 94.86
Profit After Tax 178.86 150.71 158.35 127.6 330.94
Adjusted EPS (Rs) 39.1 32.94 34.61 27.89 72.34

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 2238.55 2610.99 2424.76 2193.17 2281.35
Total Expenditure 1526.15 1775.05 1615.81 1557.85 1541.03
Operating Profit 712.4 835.94 808.95 635.32 740.32
Other Income 81.12 62.65 101.05 180.51 172.25
Interest 15.39 10.7 13.48 15.43 8.5
Depreciation 109.41 115 105.51 62.28 60.79
Exceptional Items 0 0 33 7.95 172.81
Profit Before Tax 668.72 772.89 824.01 746.07 1016.09
Tax 171.11 160.33 200.08 194.74 248.49
Net Profit 497.61 612.56 623.93 551.33 767.6
Adjusted EPS (Rs.) 108.77 133.89 136.38 120.51 167.78

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 45.75 45.75 45.75 45.75 45.75
Total Reserves 2347.29 2818.66 3161.55 3549.79 4171.66
Borrowings 0 0 0 0 0
Other N/C liabilities 85.06 136.23 38.41 32.74 54.89
Current liabilities 774.34 852.89 657.35 546.56 569.51
Total Liabilities 3252.44 3853.53 3903.06 4174.84 4841.81
Assets
Net Block 864.74 840.96 749.25 712.71 723.62
Capital WIP 2.76 1.15 7.93 0.4 7.64
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 291.62 549.2 550.26 589.78 541.34
Other N/C Assets 220.02 100.78 102.28 134.14 56.36
Current Assets 1873.3 2361.44 2493.34 2737.81 3512.85
Total Assets 3252.44 3853.53 3903.06 4174.84 4841.81
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 668.72 772.89 824.01 746.07 1016.09
Adjustment 54.53 76.17 -131.26 -89.32 -256.91
Changes in Assets & Liabilities -91.78 43.94 -34.49 -246.09 56.79
Tax Paid -204.14 -225.92 -302.58 -153.82 -156.22
Operating Cash Flow 427.33 667.08 355.68 256.84 659.75
Investing Cash Flow -468.84 -575.02 -36.05 53.7 -71.34
Financing Cash Flow -1571.07 -180.51 -345.79 -235.14 -205.34
Net Cash Flow -1612.58 -88.45 -26.16 75.4 383.07

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 63.92 63.92 63.92 63.92 63.92
john wyeth & brother ltd 1.93 1.93 1.93 1.93 1.93
parke, davis & company ll... 2.09 2.09 2.09 2.09 2.09
pfizer east india b v 39.75 39.75 39.75 39.75 39.75
pharmacia corporation 1.71 1.71 1.71 1.71 1.71
warner-lambert company ll... 2.60 2.60 2.60 2.60 2.60
wyeth holdings corporatio... 3.56 3.56 - 3.56 3.56
wyeth llc 12.28 12.28 12.28 12.28 12.28
wyeth holdings corporatio... - - 3.56 - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 36.08 36.08 36.08 36.08 36.08
atul limited 2.10 2.10 2.10 2.10 2.10
icici prudential mutual f... - - - - 1.13
investor education and pr... 0.88 - 0.88 - 0.92
life insurance corporatio... 5.79 5.79 4.31 4.07 3.93
nippon life india trustee... - - - - 4.17
quant mutual fund - - - - 2.33
sbi mutual fund - - - - 1.13
icici prudential mnc fund... - - - 1.10 -
investor education and pr... - 0.88 - 0.93 -
nippon life india trustee... - - - 3.76 -
quant mutual fund - quant... - - - 2.35 -
sbi nifty smallcap 250 in... - - - 1.52 -
nippon life india trustee... - 3.73 3.76 - -
quant mutual fund - quant... - - 2.08 - -
sbi magnum midcap fund - - 1.31 - -
nippon life india trustee... 3.75 - - - -
uti nifty midcap 150 qual... 1.02 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
Research ICICI Securities Limited
Research Nirmal Bang Institutional

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q1FY21
Concall Q4FY19
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY19

Company News

Pfizer - Quaterly Results 19 May, 10:27 PM Pfizer - Quaterly Results 19 May, 10:27 PM Pfizer informs about disclosures 19 Mar, 3:02 PM Pfizer gets nod to enter into Marketing and Supply Agreement with Mylan Pharmaceuticals 21 Feb, 3:44 PM Pfizer informs about disclosure 4 Feb, 11:56 AM Pfizer - Quaterly Results 31 Jan, 5:04 PM Pfizer - Quaterly Results 31 Jan, 5:04 PM Pfizer - Quaterly Results 31 Jan, 5:04 PM Pfizer informs about issuance of duplicate share certificates 11 Dec, 4:47 PM Pfizer - Quaterly Results 28 Oct, 6:05 PM Pfizer - Quaterly Results 28 Oct, 6:05 PM Pfizer - Quaterly Results 28 Oct, 6:05 PM Pfizer informs about newspaper publication 8 Aug, 4:58 PM Pfizer - Quaterly Results 29 Jul, 7:47 PM Pfizer - Quaterly Results 29 Jul, 7:47 PM Pfizer informs about annual secretarial compliance report 27 May, 4:31 PM Pfizer - Quaterly Results 17 May, 7:41 PM Pfizer - Quaterly Results 17 May, 7:41 PM Pfizer - Quaterly Results 9 Feb, 2:40 PM Pfizer - Quaterly Results 9 Feb, 2:40 PM Pfizer - Quaterly Results 9 Feb, 2:40 PM Pfizer informs about appointment of executive director 22 Jan, 9:41 AM Pfizer - Quaterly Results 28 Oct, 3:26 PM Pfizer - Quaterly Results 28 Oct, 3:26 PM Pfizer - Quaterly Results 28 Oct, 3:26 PM Pfizer informs about change in management 18 Aug, 4:44 PM Pfizer - Quaterly Results 11 Aug, 4:29 PM Pfizer - Quaterly Results 11 Aug, 4:29 PM Pfizer - Quaterly Results 11 Aug, 4:29 PM Pfizer informs about loss of share certificates 20 Jul, 4:56 PM Pfizer informs about loss of share certificates 20 Jun, 11:15 AM Pfizer reports marginal rise in Q4 net profit 16 May, 10:09 AM Pfizer - Quaterly Results 15 May, 5:53 PM Pfizer - Quaterly Results 15 May, 5:53 PM Pfizer informs about loss of share certificate 20 Apr, 5:03 PM Pfizer informs about issue of duplicate certificate 28 Mar, 2:46 PM Pfizer to acquire Seagen for $43 billion 14 Mar, 2:07 PM Pfizer transfers Thane business undertaking to Vidhi Research and Development 27 Feb, 10:29 AM Pfizer informs about outcome of board meeting 9 Feb, 5:21 PM Pfizer - Quaterly Results 9 Feb, 4:42 PM Pfizer - Quaterly Results 9 Feb, 4:42 PM Pfizer - Quaterly Results 9 Feb, 4:42 PM Pfizer - Quaterly Results 11 Nov, 4:15 PM Pfizer - Quaterly Results 11 Nov, 4:15 PM Pfizer - Quaterly Results 11 Nov, 4:15 PM Pfizer informs about board meeting 1 Sep, 5:24 PM Pfizer informs about unaudited financial results 5 Aug, 4:24 PM Pfizer - Quaterly Results 5 Aug, 3:10 PM Pfizer - Quaterly Results 5 Aug, 3:10 PM Pfizer - Quaterly Results 5 Aug, 3:10 PM

Pfizer Stock Price Analysis and Quick Research Report. Is Pfizer an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Pfizer and its performance over the period of time. Pfizer stock price today is Rs 5413.5.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Pfizer cash from the operating activity was Rs 659.75 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Pfizer has a Debt to Equity ratio of 0.0006 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Pfizer , the EPS growth was 39.2269 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Pfizer has OPM of 32.450961053762 % which is a good sign for profitability.
     
  • ROE: Pfizer have a average ROE of 19.6494 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Pfizer is Rs 5413.5. One can use valuation calculators of ticker to know if Pfizer share price is undervalued or overvalued.
Last Updated on:
Brief about Pfizer
X